New toolkit launched to help repurposed medicines reach patients
The toolkit helps researchers, charities and others navigate the opportunities and challenges of repurposing medicines.
LifeArc’s Head of Ventures, Clare Terlouw speaks with @FT Global Pharma Correspondent @hannahkuchler discussing RQ… https://t.co/fqrxEXr3Xf
LifeArc scientist awarded prestigious industrial fellowship
LifeArc scientist Finbar Gaffey awarded a coveted industrial fellowship from the Royal Commission for the Exhibition of 1851.
LifeArc joins forces with Cystic Fibrosis Trust and Medicines Discovery Catapult to strengthen antimicrobial discovery efforts
Pivotal partnership seeks to transform Cystic Fibrosis research
Aisling Burnand CBE, 1964-2022
It is with deep sadness that we share the news that Aisling Burnand CBE passed away on Monday 19 September 2022.
Separate science from politics: save the UK’s science sector
LifeArc's Chief Scientific Officer calls for UK science to continue to be a contributor to the Horizon Europe programme.
Promising new antibody treatment for osteoporosis and multiple sclerosis
The new antibody offers hope of an effective new treatment option for millions of people.
Her Majesty Queen Elizabeth II
We at LifeArc are deeply saddened by the passing of Her Majesty Queen Elizabeth II.
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
Seven questions about LifeArc’s 2030 ambitions
Melanie Lee talks about LifeArc’s commitment to patients, and explains why we should all care about science translation.